Since multiple signaling pathways have been associated with neuroblastoma pathogenesis, molecular therapeutics have mainly focused on inhibiting effectors of p53-MDM2, RAS-MAPK, and ALK signaling pathways. This evidence concerns the gene TP53 and neuroblastoma.